← back to search

Dihua Yu

The University of Texas MD Anderson Cancer Center · US
Area of research
Oncology · Molecular Biology
Research interest
Research interests include HER2/EGFR in Cancer Research, Cancer-related Molecular Pathways, Monoclonal and Polyclonal Antibodies Research, and RNA modifications and cancer.
h-index
85
citations
30,007
works
552
NIH funding
primary concept
Medicine
email

Recent publications

Exploring alkaloids and flavonoids from natural sources: Emerging natural agents for inhibiting cervical cancer progression through apoptosis induction, anti-inflammatory effects, and oxidative stress reduction
Pathology - Research and Practice 2025cited by 12position: middledoi
Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma
Nature Communications 2024cited by 19position: middledoi
Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis
Science Translational Medicine 2022cited by 53position: middledoi
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
Nature Communications 2021cited by 596position: middledoi
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Journal of Clinical Investigation 2021cited by 311position: middledoi
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1
Cancer Cell 2021cited by 300position: lastdoi
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells
Journal of Clinical Investigation 2021cited by 245position: middledoi
miR-7/TGF-β2 axis sustains acidic tumor microenvironment-induced lung cancer metastasis
Acta Pharmaceutica Sinica B 2021cited by 42position: middledoi
Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation
Nature Communications 2021cited by 31position: middledoi
Allergic Mediator Histamine Confers Immunotherapy Resistance in Cancer Patients <i>via</i> Histamine Receptor 1 on Macrophage
SSRN Electronic Journal 2020cited by 1position: lastdoi
The importance of developing therapies targeting the biological spectrum of metastatic disease
Clinical & Experimental Metastasis 2019cited by 13position: middledoi
Oncogenic Kinase–Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem–like Cells
Cancer Research 2018cited by 102position: lastdoi
JAK2-binding long noncoding RNA promotes breast cancer brain metastasis
Journal of Clinical Investigation 2017cited by 230position: middledoi
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Nature Communications 2016cited by 1,099position: middledoi
14-3-3ζ Turns TGF-β’s Function from Tumor Suppressor to Metastasis Promoter in Breast Cancer by Contextual Changes of Smad Partners from p53 to Gli2
Cancer Cell 2015cited by 182position: lastdoi
Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases
Stem Cells 2015cited by 52position: middledoi
Multiple Target-Specific Molecular Agents for Detection and Image Analysis of Breast Cancer Characteristics in Mice
Current Molecular Medicine 2013cited by 6position: middledoi
The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis
Cell 2012cited by 465position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mien‐Chie Hung · Institute of Biomedical Science7 papers (2012–2024)Jun Yao · Anhui Medical University7 papers (2015–2021)Yohei Saito · The University of Texas MD Anderson Cancer Center3 papers (2015–2021)Jung-Mao Hsu · University of Houston3 papers (2016–2021)Heng‐Huan Lee · University of Houston3 papers (2016–2024)Ping Li · Tongji University3 papers (2015–2021)Yi Xiao · Guangdong Medical College3 papers (2015–2021)Weiya Xia · National Yang Ming Chiao Tung University3 papers (2016–2024)Jennifer L. Hsu · The University of Texas MD Anderson Cancer Center3 papers (2016–2021)Ayşegül A. Şahin · The University of Texas Health Science Center at Houston2 papers (2015–2016)Liuqing Yang · The University of Texas MD Anderson Cancer Center2 papers (2017–2021)Xiangliang Yuan · University of Chinese Academy of Sciences2 papers (2020–2021)Hideo Yagita∥ · The University of Tokyo2 papers (2020–2021)Li-Chuan Chan · University of Houston2 papers (2016–2021)Wen‐Ling Kuo · Memorial Hospital of South Bend2 papers (2015–2021)Angela P. Halpin · The University of Texas MD Anderson Cancer Center2 papers (2020–2021)Da Pang · First People's Hospital of Foshan2 papers (2020–2021)Hirohito Yamaguchi · University of Houston2 papers (2016–2021)Hongzhong Li · Molecular Oncology (United States)2 papers (2020–2021)Jong‐Ho Cha · Inha University2 papers (2016–2021)